-
Avanir Pharmaceuticals Provides "Several Positive Developments" on European Regulatory Filing for NUEDEXTA
Tuesday, July 26, 2011 - 8:33am | 301Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect. On July 22, 2011, company officials...
-
Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson's Disease
Tuesday, July 26, 2011 - 8:31am | 125Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment in the ASCEND-PD trial. ASCEND-PD is a multinational Phase III comparative study of IPX066 to carbidopa-levodopa and entacapone in subjects with advanced...
-
UPDATE: GlaxoSmithKline Swings To Q2 Profit; Shares Rise In Pre-Market
Tuesday, July 26, 2011 - 8:21am | 70GlaxoSmithKline PLC (NYSE: GSK) swung to a second-quarter profit. GSK reported its quarterly profit at 1.11 billion pounds ($1.82 billion), versus a year-ago loss of 304 million pounds. Before restructuring charges, GSK's net profit came in at 1.27 billion pounds. Its sales dropped 4.3% to 6.72...
-
Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
Tuesday, July 26, 2011 - 7:39am | 252Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. (Tokyo:4503) today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and...
-
Mad Money Lightning Round: Cramer Likes Parker Hannifin
Tuesday, July 26, 2011 - 4:18am | 214On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Parker Hannifin (NYSE: PH) is a “very inexpensive stock and I want to buy it." Cramer said that American Capital Agency (NASDAQ: AGNC) is “under a little pressure, so I'm going to send you to Annaly Capital (NYSE: NLY)." For...
-
ULURU Unusual Trading Activity
Monday, July 25, 2011 - 8:16pm | 51ULURU (NYSE: ULU), announced in view of the unusual market activity in the common stock, the NYSE Amex has contacted the Company in accordance with its usual practice; the Company stated it is our company policy not to comment on unusual market activity.
-
Benzinga's Top ETF Decliners, July 25th (SOXL, URTY, DRN, XBI)
Monday, July 25, 2011 - 8:10pm | 186Direxion Daily Semiconductor Bull 3X Shares (NYSE: SOXL) fell 3.82% on Monday as Teradyne, Inc. (NYSE: TER) lost 2.52%, and Broadcom Corporation (NASDAQ: BRCM) dropped 1.58%. In the after hours, BRCM spiked 7.62% after posting better than expected earnings. ProShares UltraPro Russell2000 ETF (NYSE...
-
Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter
Monday, July 25, 2011 - 2:20pm | 506Celgene (NASDAQ: CELG) announces its next round of earnings this Thursday, July 28, 2011. Get the latest predictions in Benzinga's essential guide to the company's second quarter earnings report. Earnings and Revenue: Analysts are predicting an EPS reading of 77 cents per share and revenues of $...
-
Ratchet Back The Risk With These ETFs
Monday, July 25, 2011 - 2:00pm | 644Beta, the measure of a portfolio's risk relative to the broader market, can really be a four-letter word in times like these when the folks in Brussels and Washington, D.C. don't seem to have any idea which end is up. And for better or worse, there are plenty of volatile constituents populating...
-
Boston Scientific Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter
Monday, July 25, 2011 - 1:49pm | 569Boston Scientific (NYSE: BSX) announces its next round of earnings this Thursday, July 28, 2011. Get prepared with Benzinga's ultimate preview for Boston Scientific's second quarter earnings. Earnings and Revenue: Analysts are predicting an EPS reading of 8 cents per share and revenues of $1....
-
Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter
Monday, July 25, 2011 - 1:49pm | 582Vertex Pharmaceuticals (NASDAQ: VRTX) releases its next round of earnings this Thursday, July 28, 2011. Here's Benzinga's essential guide to Vertex Pharmaceuticals' second quarter earnings report. Earnings and Revenue: Analysts are bracing for a loss of 92 cents per share and revenues of $52....
-
Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter
Monday, July 25, 2011 - 12:45pm | 581Bristol-Myers Squibb (NYSE: BMY) releases its next round of earnings this Thursday, July 28, 2011. Get the latest predictions in Benzinga's essential guide to the company's second quarter earnings report. Earnings and Revenue: Analysts are looking ahead to a positive EPS of 55 cents per share...
-
Citi Comments On GSK
Monday, July 25, 2011 - 11:43am | 40According to Citi, GlaxoSmithKline (NYSE: GSK), Hold position is reiterated. Citi announced that they will be maintaining their Hold/Low-Risk position on GSK. PT is set at $41.17. GSK closed on Friday at $43.75
-
Nothing To Sneeze At Here
Monday, July 25, 2011 - 8:35am | 715Dallas, TX.-based Kimberly-Clark (NYSE: KMB) reported second quarter earnings this morning that handily beat Wall Street expectations, despite higher commodity prices for its products. The company reported earnings of $1.18 per share on $5.26 billion in revenues. Wall Street analysts were...
-
Earnings Expectations for the Week of July 25
Sunday, July 24, 2011 - 9:40am | 1439The earnings crunch continues this week even as the month of July winds to a close. Quarterly reports of note scheduled for the week include those from Netflix (NASDAQ: NFLX), United Parcel Service (NYSE: UPS), Exxon Mobil (NYSE: XOM), Starbucks (NASDAQ: SBUX), Merck (NYSE: MRK) and Dow Chemical (...